Leveraging the Immunologic Dysfunction in Bladder Cancer Through Combination Systemic Therapy
Arjun V. Balar, MD
Department of Medicine
Director, Genitourinary Medical Oncology Program
NYU Langone’s Perlmutter Cancer Center
New York, NY
Peter H. O’Donnell, MD
Assistant Professor of Medicine
Department of Medicine
University of Chicago
This live activity will cover the treatment and management of patients with bladder cancer.
This activity is designed to meet the educational needs of urologists, medical oncologists, and other health care providers involved in the referral and treatment of patients with advanced and metastatic Bladder Cancer.
On completing the program, attendees should be able to:
- Review the role of the immune system in the pathogenesis of patients with bladder cancer
- Describe the immunotherapy clinical trial data in the systemic treatment of patients with advanced or metastatic bladder cancer
- Discuss the personalization of care that incorporates shared decision-making in the management of patients with advanced or metastatic Bladder Cancer
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the treatment and management of patients with bladder cancer.
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Arjun V. Balar reports that he has served as a consultant for AstraZeneca Medlmmune; Genenlech, Inc. F. Hoffmann La Rocha Lt .; and Merck & Co., Inc, Pfizer. He has also received research grants from Merck & Co, AstraZeneca, Genentech, and Seattle Genetics.
Dr. Peter H. O’Donnell reports the following disclosures
Research Funding: Boehringer Ingelheim, Merck, Genentech/Roche, AstraZeneca/MedImmune, Acerta Pharma, Janssen, Seattle Genetics
Honoraria: Genetech/Roche, Merk, AstraZeneca, Astellas Pharma, Seattle Genentics, Inovio Pharmaceuticals, Janssen Biotech, Parexel, Xcenda,
Stock and Ownership Interest: Allergan
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
Nurse reviewer: Lynnsey Grzybowski, RN, has no relevant financial relationships to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Sharine Griggs, Program Manager for Med Learning Group, has nothing to disclose.
Cathy Herbert, Medical Writer for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.
Participants will receive their certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: January 22, 2019
EXPIRATION DATE: January 22, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.